RU2007143336A - PHARMACEUTICAL COMPOSITION BASED ON A PEPTIDE NORMALIZING URINATION AND METHOD OF APPLICATION - Google Patents
PHARMACEUTICAL COMPOSITION BASED ON A PEPTIDE NORMALIZING URINATION AND METHOD OF APPLICATION Download PDFInfo
- Publication number
- RU2007143336A RU2007143336A RU2007143336/15A RU2007143336A RU2007143336A RU 2007143336 A RU2007143336 A RU 2007143336A RU 2007143336/15 A RU2007143336/15 A RU 2007143336/15A RU 2007143336 A RU2007143336 A RU 2007143336A RU 2007143336 A RU2007143336 A RU 2007143336A
- Authority
- RU
- Russia
- Prior art keywords
- glutamyl
- glu
- asp
- seq
- sequence
- Prior art date
Links
Abstract
1. Фармацевтическая композиция, нормализующая мочеиспускание, характеризующаяся тем, что в качестве действующего вещества содержит эффективное количество пептида глутамил-аспарагиновая кислота общей формулы: H-Glu-Asp-OH последовательности 1 [SEQ ID NO:1] и фармацевтически приемлемый носитель. ! 2. Фармацевтическая композиция по п.1, отличающаяся тем, что находится в форме, подходящей для парентерального введения. ! 3. Пептид глутамил-аспарагиновая кислота общей формулы: H-Glu-Asp-OH последовательности 1 [SEQ ID NO:1]. ! 4. Пептид глутамил-аспарагиновая кислота общей формулы: H-Glu-Asp-OH последовательности 1 [SEQ ID NO:1], обладающий биологической активностью, проявляющейся в нормализации мочеиспускания путем регуляции функции детрузорно-сфинктерной системы мочевого пузыря. ! 5. Способ регуляции функции детрузорно-сфинктерной системы мочевого пузыря, заключающийся во введении пациенту фармацевтической композиции, содержащей в качестве действующего вещества эффективное количество пептида глутамил-аспарагиновая кислота общей формулы: H-Glu-Asp-OH последовательности 1 [SEQ ID NO:1] в дозе от 0,01 до 100 мкг/кг массы тела однократно ежедневно в течение 10 дней. ! 6. Способ по п.5, отличающийся тем, что введение осуществляют внутримышечно.1. A pharmaceutical composition that normalizes urination, characterized in that the active substance contains an effective amount of a glutamyl-aspartic acid peptide of the general formula: H-Glu-Asp-OH sequence 1 [SEQ ID NO: 1] and a pharmaceutically acceptable carrier. ! 2. The pharmaceutical composition according to claim 1, characterized in that it is in a form suitable for parenteral administration. ! 3. The glutamyl-aspartic acid peptide of the general formula: H-Glu-Asp-OH sequence 1 [SEQ ID NO: 1]. ! 4. The glutamyl-aspartic acid peptide of the general formula: H-Glu-Asp-OH sequence 1 [SEQ ID NO: 1], which has a biological activity that manifests itself in normalizing urination by regulating the function of the detrusor-sphincter system of the bladder. ! 5. A method for regulating the function of the detrusor-sphincter system of the bladder, which consists in administering to the patient a pharmaceutical composition containing, as active substance, an effective amount of a glutamyl-aspartic acid peptide of the general formula: H-Glu-Asp-OH sequence 1 [SEQ ID NO: 1] at a dose of 0.01 to 100 mcg / kg body weight once daily for 10 days. ! 6. The method according to claim 5, characterized in that the introduction is carried out intramuscularly.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2007143336/15A RU2367467C2 (en) | 2007-11-26 | 2007-11-26 | Peptide pharmaceutical composition normalising urination, and method of application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2007143336/15A RU2367467C2 (en) | 2007-11-26 | 2007-11-26 | Peptide pharmaceutical composition normalising urination, and method of application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007143336A true RU2007143336A (en) | 2009-06-10 |
| RU2367467C2 RU2367467C2 (en) | 2009-09-20 |
Family
ID=41023960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007143336/15A RU2367467C2 (en) | 2007-11-26 | 2007-11-26 | Peptide pharmaceutical composition normalising urination, and method of application thereof |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2367467C2 (en) |
-
2007
- 2007-11-26 RU RU2007143336/15A patent/RU2367467C2/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2367467C2 (en) | 2009-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1626055A3 (en) | Non-mammalian GnRH analogs and uses thereof in the regulation of the immune system | |
| EA200601799A1 (en) | HYDRAZIDE-CONTAINING COMPOUNDS - CFTR INHIBITORS AND THEIR APPLICATION | |
| WO2001060381B1 (en) | Nucleoside analogs with carboxamidine-modified bicyclic base | |
| RU2008126305A (en) | NEW PEPTID | |
| RU2010101892A (en) | HYALURONIDASE AND METHOD OF ITS USE | |
| RU2011139643A (en) | METHOD FOR TREATING NON-ALCOHOLIC STEATHEPATITIS IN HIGH DOSES OF URESODESOXYCHOLIC ACID | |
| RU2012124268A (en) | BENZIMIDAZOLE COMPOUNDS AND THEIR APPLICATIONS | |
| DE60003837D1 (en) | TETRAPEPTIDE THAT STIMULATES THE FUNCTIONAL ACTIVITY OF NEURONES, THIS CONTAINING PHARMACOLOGICAL AGENT AND ITS USE | |
| US20120322799A1 (en) | Deuterated compounds useful for treating neurodegenerative diseases | |
| US20220370360A1 (en) | Compositions for treating viral infections and methods for same | |
| JP2018531945A (en) | Use of peptides to stimulate the immune system | |
| US20170029391A1 (en) | Cyclohexenyl compounds, compositions comprising them and methods | |
| RU2009129212A (en) | NON-IMMUNOSUPPRESSOR CYCLOSPORIN FOR TREATMENT OF CONGENITAL MYOPATHY OF ULRICH | |
| IL194500A0 (en) | Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application | |
| RU2007119067A (en) | MEANS FOR TREATMENT OF AN IRRITATED INTESTINAL SYNDROME WITH PREVENTION OF DIARRHEA | |
| EA200700178A1 (en) | PEPTIDE, HAVING STRESS-PROTECTIVE ACTION, PHARMACEUTICAL COMPOSITION ON ITS BASIS AND ITS APPLICATION | |
| EA200700177A1 (en) | PEPTIDE OWNED WITH IMMUNOGEROPROTECTIVE ACTION, PHARMACEUTICAL COMPOSITION ON ITS BASIS AND METHOD OF ITS APPLICATION | |
| EP2272537A3 (en) | Salts of conjugated psychotropic drugs and processes of preparing same | |
| RU2007143337A (en) | PHARMACEUTICAL COMPOSITION BASED ON A PEPTIDE REGULATING AN ANGIOGENESIS DISORDER, AND METHOD OF ITS APPLICATION | |
| EA200700176A1 (en) | PEPTIDE, NORMALIZING METABOLISM IN BONE AND NURSING TISSUES, PHARMACEUTICAL COMPOSITION ON ITS BASIS AND METHOD OF ITS APPLICATION | |
| WO2017039751A1 (en) | Mutant peptides and methods of treating subjects using the same | |
| RU2007143336A (en) | PHARMACEUTICAL COMPOSITION BASED ON A PEPTIDE NORMALIZING URINATION AND METHOD OF APPLICATION | |
| CA2400872A1 (en) | Cyclic hexapeptide derivatives | |
| RU2019109154A (en) | PHARMACEUTICAL COMPOSITION FOR THERAPY OF GROWTH HORMONE DEFICIENCY, CONTAINING THE FUEL PROTEIN hGH | |
| RU2008152691A (en) | METHOD FOR PREVENTION AND TREATMENT OF MASTITIS IN COWS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| QB4A | Licence on use of patent |
Free format text: LICENCE Effective date: 20120705 |
|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20170616 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20171127 |